Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 291,500 shares, a growth of 140.3% from the October 31st total of 121,300 shares. Based on an average daily volume of 266,300 shares, the short-interest ratio is currently 1.1 days. Approximately 11.5% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Armistice Capital LLC increased its stake in shares of Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares during the period. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares during the last quarter. Finally, Opaleye Management Inc. increased its position in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Stock Up 7.7 %

Shares of NASDAQ ALGS opened at $22.99 on Thursday. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $30.00. The firm’s 50-day simple moving average is $11.25 and its 200 day simple moving average is $12.54. The company has a market cap of $82.53 million, a price-to-earnings ratio of -1.73 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.00 million. During the same quarter in the previous year, the company posted ($10.25) earnings per share. On average, equities analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).